Properties (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug
|
| gptkbp:activeDuring |
lanthanum carbonate
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Fosrenol
|
| gptkbp:clinicalTrials |
gptkb:Kidney_Disease:_Improving_Global_Outcomes_(KDIGO)
long-term management studies on efficacy studies on safety National_Kidney_Foundation_(NKF) |
| gptkbp:contraindication |
fatigue
muscle weakness bone pain hypophosphatemia hypersensitivity to lanthanum |
| gptkbp:date |
2004
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:drugInterdiction |
available online
not absorbed systemically reduces serum phosphate levels |
| gptkbp:formulation |
oral tablet
|
| gptkbp:hasPopulation |
children
adults |
| gptkbp:healthcare |
important for efficacy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fosrenol
|
| gptkbp:interactsWith |
antacids
iron supplements calcium supplements |
| gptkbp:mandates |
chronic kidney disease
dialysis patients |
| gptkbp:manufacturer |
gptkb:Shire_Pharmaceuticals
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:offers |
varies by region
|
| gptkbp:packaging |
bottle
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
monitor calcium levels
monitor serum phosphate levels |
| gptkbp:sideEffect |
nausea
diarrhea gastrointestinal disturbances constipation |
| gptkbp:skills |
500 mg
1000 mg 750 mg |
| gptkbp:storage |
room temperature
protected from moisture |
| gptkbp:triggerType |
binds phosphate in the gastrointestinal tract
|
| gptkbp:type |
lanthanum carbonate
|
| gptkbp:usedFor |
treatment of hyperphosphatemia
|